Acute myeloid leukemia (AML) is a genetically complex and heterogeneous aggressive cancer in which targeted therapies have improved outcomes but are often limited by induced resistance. This review provides a comprehensive and mechanistically driven overview of the molecular subclasses of AML mutations (including Class I, II, III, and IV mutations) and critically examines how these alterations inform therapeutic vulnerabilities. Moreover, it outlines the molecular subclasses of AML and examines key targeted agents, including FLT3 inhibitors such as Quizartinib and Gilteritinib, as well as IDH inhibitors like Ivosidenib and Enasidenib with BCL-2 inhibition (Venetoclax), and Revumenib as emerging menin-directed agent, highlighting their clinical impact. Emphasis is placed on rational combination strategies designed to simultaneously inhibit primary oncogenic drivers and compensatory survival pathways. By integrating mechanistic insights with clinical data, the review proposes a framework for precision-guided combination therapy aimed at overcoming resistance and achieving more durable remissions in AML with less side effects.